Ticker Hub
LLY — AI Analysis & Sentiment
12 recent AI-generated analyses for LLY. Sentiment and confidence insights updated continuously.
Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer
Eli Lilly's successful Phase 3 trial for Retevmo in early-stage lung cancer is a significant win, broadening the drug's market. While the immediate...
May 31, 2026Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care
Eli Lilly's presentation of strong Phase 3 data for Foundayo and retatrutide solidifies its leadership in the lucrative diabetes and obesity market...
May 28, 2026Foundayo and Zepbound now covered for millions of Americans
Eli Lilly's expanded PBM coverage for Foundayo and Zepbound is a significant growth catalyst. This move substantially broadens market access for it...
May 28, 2026Lilly announces three acquisitions to build infectious disease portfolio
Lilly's acquisitions enhance its infectious disease pipeline, offering long-term growth despite high valuation. This strategic expansion adds promi...
May 26, 2026A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia
Eli Lilly's VERVE-102 demonstrated strong efficacy and durability in Phase 1b trials, positioning it as a promising one-time treatment for hypercho...
May 25, 2026Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting
Eli Lilly's robust oncology pipeline progress, highlighted by multiple key presentations at ASCO, underpins its long-term growth trajectory and rei...
May 21, 2026Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial
Lilly's retatrutide Phase 3 results significantly de-risk a major obesity drug candidate, solidifying the company's long-term growth trajectory in ...
May 21, 2026Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials
Lilly's positive clinical results for Foundayo and Zepbound confirm long-term weight loss maintenance, significantly boosting their market potentia...
May 12, 2026Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility
Eli Lilly's substantial capital commitment to expand manufacturing and open a genetic medicine facility reinforces its long-term growth strategy. T...
May 6, 2026Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes
Eli Lilly's retatrutide delivered strong positive Phase 3 results, indicating a significant step towards commercialization of a promising new drug ...
Mar 19, 2026Lilly's EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis
Eli Lilly's EBGLYSS demonstrated strong efficacy and safety in pediatric atopic dermatitis, unlocking a substantial new market. This positive data ...
Mar 16, 2026Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight
Lilly's combination therapy of Taltz and Zepbound demonstrated superior efficacy in a Phase 3b trial for psoriasis patients with obesity, represent...
Feb 18, 2026